A rush of headlines may make it seem as if value-based contracting is taking over the pharma industry as health systems grapple with high drug costs. But a new survey from PwC finds the pricing model has yet to take off in any major way.
Only a quarter of pharma execs surveyed by PwC’s Health Research Institute have tried a value-based contract, according to the report (PDF). But though only a minority of companies are testing the waters, PwC finds they are having an “outsized influence on trade industry messaging and new policy proposals.”
Drugmakers such as Amgen, Sanofi, Novartis, and Merck & Co. have each inked value-based contracts with payers, and Express Scripts has a variety of arrangements in place, but PwC’s research says the model still has a ways to go to until it reaches widespread adoption.
As things stand, 38% percent of pharma execs feel the risks of value-based contracting are worth the benefits. In concept, 71% of drug execs believe the pricing model could help patient outcomes while rewarding innovation, according to the report, based on PwC’s survey of 101 pharma execs and 100 health insurance execs.
On the insurance side, each of the United States’ top 5 players has tried at least one value-based contract. Smaller insurers Harvard Pilgrim and Advocate Health Care have inked more than one deal apiece, according to the report, as has Optum Rx.
One vocal advocate for innovative contracting and pricing is Express Scripts chief medical officer Steve Miller, who spoke with FiercePharma in July about the company’s cost-fighting strategies. Express Scripts has introduced indication-specific pricing in cancer and inflammatory conditions, he said, to make the “best agents available to our patients, but also the least expensive agents when biosimilars come to market.”
Express Scripts is also getting refunds if patients switch drugs within a designated time frame.
For patients who change anti-inflammatory drugs in the first 90 days, drug companies pay back two-thirds of the cost, Miller said. If a drug costs $3,000 per month and a patient switches after one month, the refund is $2,000. After two months, the refund would be $4,000. Essentially, he said, it’s a “warranty” that “allows patients and doctors to have a broad list of drugs that’s available to them.”
In oncology, the company secures rebates if patients switch within 30 days.
“The goal has to be better patient outcomes and lower costs,” Miller said. “These programs give the pharma manufacturer and Express Scripts the opportunity to work together to drive those two goals.”
Even though value-based pricing hasn’t made its way to the mainstream quite yet, according to PwC’s findings, the group notes that pricing pressure is “coming from every direction.” That pressure could force companies to adapt and further justify their prices. The group also notes that experimenting with contracting in the U.S. could assist with new launch strategies in emerging markets.
By Eric Sagonowsky
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.